ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Communication and correspondence on S. 1895, the Lower Health Care Costs Act, support for S. 659, Biologic Patent Transparency Act, support for S. 340/H.R. 965, the CREATES Act, support to changes in 42 C.F.R. Chapter 2, dissemination of materials on pharmaceutical information exchange (including amendment to S. 1895 offered by Senator Burr) and issues related to H.R. 3, Lower Drug Costs Now Act of 2019 and S. 2543 Prescription Drug Pricing Reduction Act of 2019
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP A. BONGIORNO New | VP of Policy and Government Relations |
| AFTON WAGNER New | Director of Regulatory Affairs and Director of Government Relations |
Medicare/Medicaid MMM
Communication and correspondence related to rising costs of drugs under Medicare and Medicaid, electronic prescribing, prior authorization and electronic prior authorization. Sent Dec. 16th letter to Reps. DeGette and Upton on 21st Century Cures 2.0. Submitted comments to HHS on OIG/revisions to safe harbors under the anti-kickback statute.
| Lobbyist | Covered position, as disclosed |
|---|---|
| PHILLIP A. BONGIORNO New | VP of Policy and Government Relations |
| AFTON WAGNER New | Director of Regulatory Affairs and Director of Government Relations |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.